Literature DB >> 9734544

Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.

G Tsai1, D C Goff, R W Chang, J Flood, L Baer, J T Coyle.   

Abstract

OBJECTIVE: Tardive dyskinesia is a movement disorder affecting 20%-40% of patients treated chronically with neuroleptic drugs. The dopamine supersensitivity hypothesis cannot account for the time course of tardive dyskinesia or for the persistence of tardive dyskinesia and the associated structural changes after neuroleptics are discontinued. The authors hypothesized that neuroleptics enhance striatal glutamatergic neurotransmission by blocking presynaptic dopamine receptors, which causes neuronal damage as a consequence of oxidative stress.
METHOD: CSF was obtained from 20 patients with schizophrenia, 11 of whom had tardive dyskinesia. Markers for oxidative stress, including superoxide dismutase, lipid hydroperoxide, and protein carbonyl groups, and markers for excitatory neurotransmission, including N-acetylaspartate, N-acetylaspartylglutamate, aspartate, and glutamate, were measured in the CSF specimens. Patients were also rated for tardive dyskinesia symptoms with the Abnormal Involuntary Movement Scale.
RESULTS: Tardive dyskinesia patients had significantly higher concentrations of N-acetylaspartate, N-acetylaspartylglutamate, and aspartate in their CSF than patients without tardive dyskinesia when age and neuroleptic dose were controlled for. The significance of the higher levels of protein-oxidized products associated with tardive dyskinesia did not pass Bonferroni correction, however. Tardive dyskinesia symptoms correlated positively with markers of excitatory neurotransmission and protein carbonyl group and negatively with CSF superoxide dismutase activity.
CONCLUSIONS: These findings suggest that there are elevated levels of oxidative stress and glutamatergic neurotransmission in tardive dyskinesia, both of which may be relevant to the pathophysiology of tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9734544     DOI: 10.1176/ajp.155.9.1207

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  36 in total

Review 1.  Oxidative mechanisms and tardive dyskinesia.

Authors:  James B Lohr; Ronald Kuczenski; Alexander B Niculescu
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  [Effect of antipsychotics on glutaminergic neural transmission in the animal model].

Authors:  A Schmitt; B May; B Müller; M Zink; D F Braus; F A Henn
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 3.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

4.  Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: cellular and neurochemical evidence.

Authors:  Mahendra Bishnoi; Kanwaljit Chopra; Lu Rongzhu; Shrinivas K Kulkarni
Journal:  Neurotox Res       Date:  2010-11-13       Impact factor: 3.911

5.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

6.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

7.  Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia.

Authors:  Takahiro Shinkai; Osamu Ohmori; Chima Matsumoto; Hiroko Hori; James L Kennedy; Jun Nakamura
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

8.  The effects of ziprasidone, clozapine and haloperidol on lipid peroxidation in human plasma (in vitro): comparison.

Authors:  Anna Dietrich-Muszalska; Justyna Kopka; Anna Kwiatkowska
Journal:  Neurochem Res       Date:  2013-04-26       Impact factor: 3.996

9.  Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.

Authors:  Mahendra Bishnoi; Kanwaljit Chopra; Shrinivas K Kulkarni
Journal:  Psychopharmacology (Berl)       Date:  2007-10-23       Impact factor: 4.530

10.  Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia.

Authors:  Jing Qin Wu; Da Chun Chen; Yun Long Tan; Shu Ping Tan; Li Hui; Men Han Lv; Jair C Soares; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-07-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.